Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.
) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 1.0%. By the end of trading, Eli Lilly and Company rose $0.74 (1.5%) to $51.23 on average volume. Throughout the day, 5,094,675 shares of Eli Lilly and Company exchanged hands as compared to its average daily volume of 6,159,700 shares. The stock ranged in a price between $50.40-$51.24 after having opened the day at $50.52 as compared to the previous trading day's close of $50.49. Other companies within the Drugs industry that increased today were:
), up 35.5%,
), up 14.6%,
), up 14.6% and
), up 14.4%.
- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. Eli Lilly and Company has a market cap of $57.1 billion and is part of the health care sector. The company has a P/E ratio of 11.6, below the S&P 500 P/E ratio of 17.7. Shares are up 2.4% year to date as of the close of trading on Thursday. Currently there are 5 analysts that rate Eli Lilly and Company a buy, 2 analysts rate it a sell, and 7 rate it a hold.
TheStreet Ratings rates
Eli Lilly and Company
. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, attractive valuation levels and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income.
- You can view the full Eli Lilly and Company Ratings Report.
On the negative front,
), down 38.6%,
), down 11.9%,
), down 11.5% and
), down 8.3% , were all laggards within the drugs industry with
) being today's drugs industry laggard.
- Use our drugs section to find industry-relevant news.
- Or find some new ideas from our top rated stocks lists.
For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider
) while those bearish on the drugs industry could consider
- Find other investment ideas from our top rated ETFs lists.